undamentalytics Newsletter
Sign in

Repligen Corp income statement

In fiscal 2025, Repligen Corp reported revenue of $738m, up 16.4% on the year before, operating income of $55.2m (a 7.5% margin) and net income of $48.9m, or $0.86 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Mar 20102011Mar 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue212762686484105141194270366671802632634738806
Cost of revenue——————476787119157279346354360352375
Gross profit——————5774108151210391456278275386431
Research and development14131076679161920344443435457
Selling, general and administrative781313172531526696120184216219263291312
Operating income−6−011231114161426367016722548−355518
Interest expense0000004679111112212222
Income before tax−5−01123111312721265915421957−27628
Income tax−1—−37340−2155−1253321−21320
Net income−4—141689122817216012818636−2649−12
Diluted EPS−$0.13$0.00$0.45$0.50$0.25$0.28$0.34$0.72$0.37$0.44$1.11$2.24$3.24$0.63−$0.46$0.86—
Diluted shares (average)31m31m31m32m33m34m34m39m45m49m54m57m57m56m56m57m—
EBITDA−411526151821254257972062761163513496

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NEO vs RGENRGEN vs TXGAZTA vs RGENRGEN vs TECH

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Repligen Corp's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Repligen Corp.